Special Issue

Combined Locoregional-Immunotherapy for Cancer Treatment

Message from the Guest Editors

Immunotherapy has changed the landscape of cancer treatment in the past several years. The systemic administration of immune checkpoint inhibitors (ICIs), targeting PD-1, PD-L1, or CTLA-4, is the pillar of current immunotherapy. However, it is notable that ICIs have limited efficacy as monotherapy, and their greatest potential lies in combination with other treatments that can trigger or augment anti-tumour immune responses. Accumulating preclinical data suggest that the locoregional delivery of immunotherapy agents (e.g., TLR/STING agonists, antibodies, or viruses) can induce robust systemic antitumor immunity in various types of cancers. However, one of the major setbacks of locoregional immunotherapy is that many cancers in the clinic are not easily accessible compared with preclinical tumour models. Therefore, its clinical utilization will inevitably require image-guidance. The purpose of this Special Issue is to collect studies regarding locoregional immunotherapies from researchers in the field of immuno-oncology and interventional oncology in order to promote new opportunities and perspectives by bridging the gap between the fields.

Guest Editors

Dr. Heegon Kim

Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

Prof. Dr. Dong-Hyun Kim

Department of Radiology, Northwestern University Feinberg, School of Medicine, Chicago, IL 60611, USA

Deadline for manuscript submissions

closed (20 August 2021)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/75926

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

